RxSight, Inc. (RXST)
NASDAQ: RXST · Real-Time Price · USD
9.28
+0.55 (6.30%)
At close: Aug 22, 2025, 4:00 PM
9.11
-0.17 (-1.83%)
After-hours: Aug 22, 2025, 7:46 PM EDT
RxSight Revenue
RxSight had revenue of $33.64M in the quarter ending June 30, 2025, a decrease of -3.58%. This brings the company's revenue in the last twelve months to $147.06M, up 27.68% year-over-year. In the year 2024, RxSight had annual revenue of $139.93M with 57.09% growth.
Revenue (ttm)
$147.06M
Revenue Growth
+27.68%
P/S Ratio
2.55
Revenue / Employee
$295,299
Employees
498
Market Cap
379.70M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 139.93M | 50.85M | 57.09% |
Dec 31, 2023 | 89.08M | 40.07M | 81.77% |
Dec 31, 2022 | 49.01M | 26.41M | 116.90% |
Dec 31, 2021 | 22.59M | 7.92M | 53.92% |
Dec 31, 2020 | 14.68M | 12.44M | 554.98% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2004 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2003 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
RXST News
- 8 hours ago - RXST CLASS REMINDER: Suffer Losses on Your RxSight, Inc. Investment? Contact BFA Law before the September 22 Court Deadline (NASDAQ:RXST) - GlobeNewsWire
- 1 day ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight - GlobeNewsWire
- 2 days ago - Shareholders who lost money on their RxSight, Inc. (NASDAQ: RXST) Investment Should Contact Wolf Haldenstein Immediately as the Lead Plaintiff Deadline is September 22nd - PRNewsWire
- 5 days ago - RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - RXST - PRNewsWire
- 10 days ago - RXSIGHT STOCK: Lose Money on Your RxSight, Inc. (NASDAQ:RXST) Investment? Contact BFA Law before the September 22 Legal Deadline - GlobeNewsWire
- 12 days ago - RXST COURT NOTICE: RxSight, Inc. Investors may have been Affected by Fraud -- Contact BFA Law before September 22 if You Suffered Losses (NASDAQ:RXST) - GlobeNewsWire
- 15 days ago - RxSight, Inc. (RXST) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - RxSight, Inc. Reports Second Quarter 2025 Financial Results - GlobeNewsWire